Seeking Alpha

DURECT strikes deal with Impax to get Eladur back into development

  • Impax Labs (IPXL -1.7%) and DURECT (DRRX +5.6%) announce a development and commercialization agreement for the PHN patch, Eladur.
  • IPXL is paying $2M upfront for exclusive worldwide rights.
  • Additional payments could reach $61M depending upon "the achievement of predefined development and commercialization milestones."
  • DRRX also gets royalties assuming the patch reaches the market.
  • IPXL is controlling and funding development. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: